Sigma-Proligo Expands Into Genopole(R) d'Evry Biopark
Sigma-Proligo, a division of the Sigma-Aldrich group (Nasdaq: SIAL), announced it has acquired 2,000 sq. meters of office space in the heart of the Genopole(R) d'Evry biopark in the region of Paris.
Sigma- Proligo has 65 employees in France, the majority of whom are researchers. Thanks to an R&D team, which is also based in Evry, the site is expected to become a center of excellence within the Sigma-Aldrich group. The new facility is expected to provide the capacity needed for the Company to advance the production of high-quality oligonucleotides in order to meet emerging needs within the bioscience research sector.
"The 'biotech' image of Genopole, as well as the offices and working environment perfectly adapted to our operations, have been the main reasons behind our expansion into Evry," said Khalil Arar, operations manager of Sigma-Aldrich Evry. "The RNAi market has a predicted compound annual growth rate of 14%, and these new facilities are expected to provide Sigma-Proligo with the capacity to meet the increasing market demand for RNAi products. The facilities should also enable the Company to continue to supply customers with innovative products."
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
